Search

Ofev®

Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype

Joint Modern Slavery & Child Labor Statement 2023

PF-ILD_Infographic.pdf

786210196-001-PF-ILD_Media_Backgrounder.pdf

Wireframes_UI About us - Blueprint for building Levels 1-3.pdf

Infographic RA-ILD

Building Lasting Partnerships for a Better Future

Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.

FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF

FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis

Scleroderma

Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs

License to develop new fibro-inflammatory disease treatments

Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study

Respiratory

Human Pharma Clinical Pipeline Respiratory therapeutic area

IL-11 inhibitor antibody clinical development launched

Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment

Boehringer-Ingelheim's-half-year-figures-2021

Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.

ACR19 SENSCIS Mycophenolate

ACR Congress 2019 abstract analysing a subgroup of patients in the SENSCIS® trial in patients with SSc-ILD by use of mycophenolate at baseline

ACR19 demographic trial

ACR Congress 2019 abstract analysing the safety and tolerability of nintedanib in SSc-ILD patients in the SENSCIS® trial in a demographic subgroup

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.

Pride Month 2023: Why belonging matters – to all of us

LGBTIQ+ community members and their allies share how we can create a welcoming and inclusive culture where everyone feels heard, accepted and appreciated.

Investigational treatment slowed lung function decline in IPF

Better Access to Healthcare for Indigenous Peoples

Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.

2020-Positive-business-momentum-despite-COVID-19-impact

While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.

Zongertinib positive results non-small cell lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers